NCT04450160View on ClinicalTrials.gov

Trial of AEO in New Glioblastoma (GBM)

PHASE2UnknownINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

December 31, 2020

Primary Completion Date

July 31, 2022

Study Completion Date

September 30, 2022

Conditions
Glioblastoma Multiforme
Interventions
DRUG

Anhydrous Enol-Oxaloacetate (AEO)

Oral supplementation with AEO along with the Standard of Care (Temozolomide)

OTHER

Standard of Care

Standard of Care Temozolomide

Sponsors

Lead Sponsor

MetVital, Inc.
All Listed Sponsors
lead

MetVital, Inc.

INDUSTRY

NCT04450160 - Trial of AEO in New Glioblastoma (GBM) | Biotech Hunter | Biotech Hunter